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Hepatitis B virus (HBV) core-derived chimeric particles carrying a Puumala (PUU) hantavirus (strain Vranica/Ha¨llna¨s)
nucleocapsid (N) protein sequence (aa 1–45), alternatively inserted at three distinct positions (N-, C-terminus, or the internal
region), and mosaic particles consisting of HBV core as well as core/PUU (Vranica/Ha¨llna¨s) N (aa 1–45) readthrough protein
were generated. Chimeric particles carrying the insert at the N-terminus or the internal region of core induced some
protective immune response in bank voles (Clethrionomys glareolus) against a subsequent PUU virus (strain Kazan)
challenge; 40–50% of the animals showed markers of protection. In contrast, internal insertion of PUU strain CG18–20 N (aa
1–45) into the HBV core caused a highly protective immune response in the bank vole model. Immunizations with particles
carrying aa 75–119 of PUU (CG18–20) N at the C-terminus of core verified the presence of a second, minor protective region
in the N protein. A strong PUU N-specific antibody response was detected not only in bank voles immunized with chimeric
particles containing internal and N-terminal fusions of PUU N protein but also in animals immunized with the corresponding
mosaic particles. Except for the exclusive occurrence of antibodies directed against aa 231–240 of N in non-protected
animals post virus challenge, there was no additional obvious difference in the epitope-specificity of N-specific antibodies
from immunized animals prior and post virus challenge. © 2000 Academic Press
Key Words: HBV core particles; insertion sites; hantavirus; nucleocapsid protein; epitope scanning.
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1INTRODUCTION
Core particles of the hepatitis B virus (HBV) have been
shown to improve the immune response against foreign
epitopes presented on their surface by providing T-cell
help for the induction of antibodies. In addition, core
particles are not only T-cell-dependent but also T-cell-
independent antigens (Milich et al., 1986; Fehr et al.,
1998). Protective immunity against various viral infec-
tions has been induced by chimeric core particles in
animal models (Neirynck et al., 1999; for a review see
Ulrich et al., 1998a). Different insertion sites for foreign
epitopes were identified in the HBV core protein (HBc) by
computer predictions, and empirical and epitope map-
ping studies (for reviews see Scho¨del et al., 1994;
Pumpens et al., 1995; Ulrich et al., 1998a; Pumpens and
Grens, 1999). The most promising insertion site was
found to be the major conformation-dependent B-cell
epitope “c” mapped around aa position 80 overlapping
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364with “e1”, one of two major HBe determinants (Salfeld et
al., 1989; Pushko et al., 1994). By cryo-electron micros-
copy the c/e1 epitope region of HBc was demonstrated
to be localized in a surface-exposed loop (Bo¨ttcher et al.,
1997; Conway et al., 1997). These data are confirmed by
the crystal structure of the HBV core (Wynne et al., 1999).
Recently the c/e1 site was shown to tolerate the insertion
of large foreign proteins (Koletzki et al., 1999; Kratz et al.,
1999). Further insertion sites at the N-terminus and at
various C-terminal positions of HBc have been proven to
expose, at least in part, the inserted sequences on the
surface of chimeric particles (for reviews see Scho¨del et
al., 1994; Pumpens et al., 1995; Ulrich et al., 1998a).
owever, if compared to foreign sequences inserted at
he c/e1-loop, the antigenicity and immunogenicity of
oreign sequences in N- and C-terminal fusions was
onsiderably lower (Brown et al., 1991; Scho¨del et al.,
992; von Brunn et al., 1993).
Recently, we have evaluated in a systematic study the
potential usefulness of the various HBc insertion sites
carried out by inserting the same model sequence. Using
a pentapeptide sequence the extraordinary value of the
c/e1-loop insertion site was demonstrated. Neverthe-
less, the N-terminal insertion site also allowed a distinct,
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365CHIMERIC HBV CORE/PUU N PARTICLESbut lower, surface exposure of this very short foreign
sequence (Lachmann et al., 1999). Here we continued
the evaluation of potential insertion sites in HBc by the
construction of HBc fusion proteins containing a medi-
um-sized foreign sequence. As a model sequence we
selected the N-terminal 45 aa part of the hantavirus PUU
N protein since this region has previously been demon-
strated to be protective against hantavirus challenge in
an animal model (Ulrich et al., 1998b).
Hantaviruses belong to the family of Bunyaviridae and
ay cause life-threatening hemorrhaghic fever with re-
al syndrome (HFRS) or hantavirus pulmonary syndrome
HPS) in humans. Since a HPS outbreak in the Four
orners region of the United States in 1993 these viruses
ave attracted attention and have been defined as mem-
ers of the group of so-called “emerging viruses” (for
eviews see Mertz et al., 1997; Schmaljohn and Hjelle,
997; Plyusnin et al., 2000). Due to its immunogenicity the
protein of hantaviruses could offer many advantages
s a subcomponent vaccine. Its immunogenicity is inde-
endent of post-translational modifications and its N-
erminal region (of PUU strain Sotkamo) was able to
rotect laboratory animals against an infection by a re-
ated PUU virus (Lundkvist et al., 1996). In addition, this
egion of the PUU N protein was shown to contain
everal B-cell epitopes determining its immunodominant
eature (Lundkvist et al., 1996; Elgh et al., 1996; Go¨tt et al.,
997; our unpublished data). Similar properties of the N
roteins of other hantavirus serotypes have been de-
cribed (Jenison et al., 1994; Yamada et al., 1995; Elgh et
l., 1997; Yoshimatsu et al., 1996).
The objectives of the present study were: 1) a com-
arison of insertion sites in HBc in terms of antigenicity,
mmunogenicity, and protectivity excerted by inserting a
5 aa-long PUU (Vranica/Ha¨llna¨s) N sequence; 2) a com-
arison of the protective potential of this N region from
wo different PUU strains (Vranica/Ha¨llna¨s vs. CG18–20)
nserted into the same site of HBc against challenge with
UU virus (strain Kazan); 3) a comparison of the protec-
ive potential of this region from PUU CG18–20 if pre-
ented on core particles or used as a synthetic peptide
gainst challenge; 4) a comparison of the epitope-spec-
ficity of the PUU N-specific antibody response prior and
ost virus challenge; and 5) an increase of the protectiv-
ty of core particles against PUU virus challenge by
ombining the major protective region (aa 1–45) with a
inor protective region of PUU N (aa 75–119) in one core
article.
RESULTS
eneration and antigenicity of HBV core-derived
articles
To study the value of three different insertion sites
N-terminus, C-terminus behind aa 144, and c/e1 region
t aa 78) within a C-terminally truncated HBV core, the
d
(-terminal 45 aa-long putative major protective region of
UU virus (strain Vranica/Ha¨llna¨s) N protein was fused to
hese three positions of HBV core (see Fig. 1A). To
enerate mosaic particles (fusion at the C-terminus), we
pplied a previously described cloning and expression
trategy (Koletzki et al., 1997).
The expression of the HBV core-derived proteins with
heir predicted molecular weights of approximately 23
Da was confirmed in Coomassie Blue-stained SDS-
AGE and by immunoblotting using polyclonal anti-HBc/
Be- and Vranica/Ha¨llna¨s N protein-specific rabbit sera
data not shown). Each of the different chimeric HBV
ore-derived proteins was able to form core-like particles
s demonstrated by negative staining electron micros-
opy, although in very different quantities. While the HBV
ore control, the c/e1, and the mosaic expression prod-
cts readily assembled to high and comparable particle
oncentrations, only low amounts of particles were ob-
erved in samples of the N- and C-terminal fusion pro-
eins (data not shown).
To determine the HBV core antigenicity, the purified
articles were applied to a HBc-specific sandwich ELISA
Fig. 2A). We observed a clear HBc-antigenicity for all
article-enriched samples, but with significant differ-
nces between the constructs. The highest core antige-
icity was found for the core control, the c/e1 insert
articles, and the mosaic particles. The C-terminal con-
truct showed a slightly lower HBc-antigenicity, whereas
he N-terminal construct revealed only weak reactivity in
he HBc sandwich ELISA.
The surface exposure of foreign sequences on core-
ike particles has been demonstrated to be a major
rerequisite for their high humoral immunogenicity.
herefore, we determined the surface exposure of the
nserted PUU N protein sequence as the PUU N antige-
icity on native core-like particles by a sandwich ELISA
Fig. 2B). All core-like fusion particles demonstrated a
easurable PUU N antigenicity, suggesting an accessi-
ility of the inserted N sequence. However, the c/e1
nsert particles excelled by the highest PUU N antigenic-
ty. In comparison to the construct with internal insertion,
he C-terminal fusion and the mosaic particles reacted in
he ELISA to a much less extent. In line with the weak
BV core antigenicity, the N-terminal construct showed
he lowest PUU N antigenicity.
BV core-like particles carrying PUU
Vranica/Ha¨llna¨s) insertions are highly
mmunogenic in bank voles
To compare the immunogenicity of the core-like parti-
les, bank voles (the natural host of PUU virus) were
mmunized using a three-dose immunization scheme. An
mmune response against the HBV core itself was in-
uced in 20 out of 24 animals prior to virus challenge
Fig. 3). In all animals immunized with core itself (animals
p
C
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366 KOLETZKI ET AL.1A–E) and mosaic particles (animals 5A–E) HBc-specific
antibodies were detected. Whereas four out of five ani-
mals immunized with the c/e1 (animals 3A, B, C, E) and
the C-terminal construct (animals 4A, B, C, E) showed a
significant core-specific immunogenicity, in the case of
the N-terminal fusion only in two out of four animals a
very weak immune response against core (with sample/
cut off ratios of 1.1 and 1.7) could be detected.
With regard to the immune response directed against
the foreign protein determinants, the N-terminal and the
c/e1 constructs were highly immunogenic in bank voles
as determined by the ELISA based on the N protein aa
1–213 (strain Vranica/Ha¨llna¨s, VR213). In contrast, the
C-terminal and the mosaic particles induced a significant
weaker response (Fig. 3). Although the two latter con-
structs did not show large differences in their ability to
induce a HBV core-specific immunogenicity, the mosaic
particles turned out to cause a stronger antibody re-
FIG. 1. Structure of the HBV core/PUU N protein fusions. (A) Fusion p
N-terminal 45 aa of PUU N (strain Vranica/Ha¨llna¨s) was generated by P
different positions within the HBV core-encoding plasmids (for plasmid
was fused to different positions of a C-terminally truncated HBV
immunodominant c/e1 region (pHBc1–78/VR45/78–144), C-terminally (p
aa 144 of HBV core (pHBc1–144/TGA/VR45). The latter construct was g
recently (Koletzki et al.,1997). (B) Fusion proteins carrying PUU N seg
HBc-N1(CG)) and pHBc1–144/CG75–119 (formerly pHBc-N3(CG)) en
G18–20) have been published already (Ulrich et al., 1998b). The gener
insertion (formerly pHBc-N1–78 (CG)/N3–144 (CG)) has been described
of the N-terminal 45 aa of the PUU strains Vranica/Ha¨llna¨s (Reip et al.,
azan (Lundkvist et al., 1997).sponse in bank voles against the hantavirus insert as
compared to the simple C-terminal construct. In addition,in the case of the C-terminal fusion particles, two out of
five animals did not show any N-specific antibody re-
sponse prior to virus challenge (animals 4B, 4C).
Induction of protective immunity in bank voles
by core particles carrying N protein aa 1–45
of Vranica/Ha¨llna¨s versus CG18–20
To investigate whether the protection depends on: 1)
the insertion site of the PUU (Vranica/Ha¨llna¨s) N se-
quence in HBV core, 2) the strain origin of the PUU N
sequence (Vranica/Ha¨llna¨s versus CG18–20) or 3) the
mode of delivery of the PUU N sequence (core-like par-
ticles versus synthetic peptide), challenge experiments
with live PUU virus (strain Kazan) were performed in the
bank vole model. The protection was measured on the
basis of the absence of viral N antigen in lungs and of
viral glycoprotein (G2)-specific antibodies in the serum of
carrying PUU N (strain Vranica/Ha¨llna¨s). The coding sequence for the
plification and inserted into a unique BamHI restriction site located at
Ulrich et al., 1999). Thereby the 45 aa–long sequence of the N protein
a 1–144); it was inserted N-terminally (pVR45/HBc1–144), into the
44/VR45), or behind a TGA stop codon which is located at the back of
d to exploit a t-RNA–mediated TGA suppressor mechanism described
of strain CG18–20. The constructs pHBc1–78/CG45/78–144 (formerly
the N-terminal aa 1–45 and 75–119, respectively, of PUU N (strain
the construct pHBc1–78/CG45/78–144/CG75–119 with a simultaneous
y (Ulrich et al., 1999). (C) Comparison of the amino acid (aa) sequences
G18–20 (Stohwasser et al., 1990), Sotkamo (Vapalahti et al., 1992) androteins
CR am
s see
core (a
HBc1–1
enerate
ments
coding
ation of
recentlthe animals three weeks after virus challenge. Protection
was found only in the groups vaccinated with the c/e1
i
s
C
t
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367CHIMERIC HBV CORE/PUU N PARTICLESand the N-terminal insert constructs (Table 1): two out of
five animals immunized with the c/e1 construct (pHBc1–
78/VR45/78–144) demonstrated an absence of anti-G2
antibodies after virus challenge, suggesting a partial
protection (animals 3B and C, Fig. 3). The N-terminal
construct (pVR45/HBc1–144) induced complete protec-
tion in one out of four (animal 2C, Fig. 3) and a partial
protection in one additional animal (2A, Fig. 3). In line
with previous data (Ulrich et al., 1998b), in a new immu-
nization experiment four out of five animals immunized
with chimeric particles formed by pHBc1–78/CG45/78–
144 (see Fig. 1B) were completely protected against the
hantavirus challenge (Table 1). As a non-particulate con-
trol a synthetic PUU N peptide (aa 1–45, strain CG18–20)
was included in the immunization experiments; none of
the respective animals was protected against virus chal-
lenge (Table 1). In addition, N-specific antibodies were
observed only in two out of five animals immunized with
the synthetic peptide (data not shown).
Epitope-specifity of PUU N protein-specific antibodies
in bank voles prior and after challenge
The humoral immune response of bank voles was
characterized to: 1) compare the antigenic fine structure
FIG. 2. Analysis of the HBV core and PUU N antigenicity of chimeric
and mosaic HBV core/PUU (Vranica/Ha¨llna¨s) N particles. (A) HBV core
antigenicity as measured by an HBV core-specific sandwich ELISA
using anti-HBc capture antibodies. (B) PUU N antigenicity determined
by a PUU N-specific sandwich ELISA using anti-HBc capture antibod-
ies. s/c: sample value/cutoff value.of the PUU N sequence presented on core-like particles
(Vranica/Ha¨llna¨s N aa 1–45 at different sites; Vranica/
w
iHa¨llna¨s vs. CG18–20) or as a synthetic peptide; and 2)
search for potential differences in the epitope-specificity
of the antibody response in non-protected vs. partially/
completely protected animals prior and after virus chal-
lenge. Therefore, the respective serum pools of the non-
protected, protected, and partially protected animals
were analyzed by a PEPSCAN assay covering the com-
plete N protein of PUU (strain Sotkamo) in 10mer pep-
tides with an overlapping sequence of 5 aa.
Two main peaks of reactivity were observed in the
serum pools of pre-challenge sera (Table 2), the first one
occurring with peptides aa 1–10 and 6–15. Notably, all
HBV core-derived particles induced an immune re-
sponse against the very N-terminal aa 1–10 and/or aa
6–15 of the N protein, whereas the synthetic peptide did
not. A second peak of reactivity was found around aa
31–40 and 36–45. Interestingly, exclusively the serum
pool of animals immunized with the CG18–20 peptide aa
1–45 as well as the pool from protected animals immu-
nized with the c/e1 insert particles carrying N protein of
PUU (CG18–20) showed the presence of antibodies di-
rected against aa 31–40 (N protein of Sotkamo, for com-
parison of sequences see Fig. 1C). Only mosaic particles
carrying PUU N (strain Vranica/Ha¨llna¨s) were able to
induce a strong antibody response directed against aa
36–45, except a weak reactivity in non-protected animals
immunized with the respective c/e1 insert particles. Ad-
ditional reactive peptides were observed which reacted
with only single pre-challenge serum pools.
Comparisons of the post-challenge sera of both pro-
tected, partially protected, and non-protected animals by
the PEPSCAN assay revealed no significant differences
in the reactivity patterns observed, with one single ex-
ception. It was striking that all non-protected animals
immunized with core-like particles (even the HBV core
control) or the peptide (aa 1–45) produced a distinct
humoral immune response against aa 231–240 after PUU
virus challenge (Table 2).
Simultaneous insertion of aa 1–45 and 75–119
of PUU (CG18–20) N protein
To evaluate the possibility of improving the protective
potential of core-like particles, recently chimeric parti-
cles have been generated harboring simultaneous inser-
tions of aa 1–45 and aa 75–119 of PUU (CG18–20) N
protein at aa positions 78 and 144 (see Fig. 1B), respec-
tively, of HBV core (Ulrich et al., 1999). By comparing the
mmunogenicity in bank voles to those of the original
ingle constructs (pHBc1–78/CG45/78–144, pHBc1–144/
G75–119) we were able to demonstrate that core par-
icles with the simultaneous insertions at aa positions
8 and 144, respectively, induced antibodies directed
gainst both protein sequences (data not shown). In line
ith our previous data (Ulrich et al., 1998b) demonstrat-
ng a partial protection of one out of four animals immu-
368 KOLETZKI ET AL.FIG. 3. Immunogenicity of core particles carrying inserts from PUU (strain Vranica/Ha¨llna¨s) N protein detected by anti-HBc and anti-PUU
(Vranica/Ha¨llna¨s) N (aa 1–213) ELISAs.
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369CHIMERIC HBV CORE/PUU N PARTICLESnized with particles carrying aa 75–119 of PUU (CG18–
20) N, again one out of four animals immunized with
these particles was completely protected against virus
challenge confirming a second minor protective region in
the N-terminus of PUU N (Table 1). However, simulta-
neous insertion of the two regions into different insertion
sites of the HBV core carrier molecule did not increase
the protectivity as compared to the construct pHBc1–78/
CG45/78–144 with a single internal insertion of aa 1–45
(strain CG18–20; see Table 1).
DISCUSSION
HBV core particles have been reported to tolerate the
insertion of foreign sequences at certain sites (N-termi-
nus, c/e1 region, C-terminus). In respect to vaccine de-
velopment the insertion site of choice should: 1) tolerate
the insertion of the foreign antigenic region without dis-
turbing formation of core-like particles; 2) expose the
foreign insert on the surface of the particles to be highly
antigenic and immunogenic; and 3) present the foreign
insert in a way inducing a protective immune response.
In the present study, when testing the three possible
insertion sites in the HBV core protein (N-, C-terminus,
and the c/e1 region) by the insertion of a 45 aa long
putative protective region of the PUU N protein for par-
ticle formation, we found, in line with previous data about
T
Protectivity of Core Particles Ca
Immunogen
pHBc1-144
HBV core
pVR45/HBc1-144
HBV core 1 PUU (VR/H) N aa 1–45/N-terminal fusion
pHBc1-78/VR45/78-144
HBV core 1 PUU (VR/H) N aa 1–45/c/e1 insertion
pHBc1-144/VR45
HBV core 1 PUU (VR/H) N aa 1–45/C-terminal fusion
pHBc1-144/TGA/VR45
HBV core mosaic particles PUU (VR/H) N aa 1–45/C-terminal
pHBc1-78/CG45/78-144
HBV core 1 PUU (CG18-20) N aa 1–45/c/e1 insertion
pHBc1-144/CG75-119
HBV core 1 PUU (CG18-20) N aa 75–119/C-terminal fusion
pHBc1-78/CG45/78-144/CG75-119
HBV core 1 PUU (CG18-20) N aa 1–45/c/e1 insertion 1 aa 75–119/C-
Synthetic peptide
PUU (CG18-20) N aa 1–45
Non-immunized, challenged
Non-immunized, non-challenged
a Partially protected.the insertion of a model pentapeptide (Lachmann et al.,
1999), that all constructs were able to form chimeric
1
rparticles. In contrast to the insertions of the short pen-
tapeptide, the PUU N fusions at the N- and C-termini
impaired the assembly capability of HBV core dramati-
cally. This observation is in line with previous results
demonstrating a reduced core antigenicity and a lower
stability of particles with N- or C-terminal insertions
(Stahl and Murray, 1989; Birnbaum and Nassal, 1990;
Ulrich et al., 1993; Maaben et al., 1994). In this context,
he reduced antigenicity of our expression products
ight be explained by structural alterations within the
ore protein caused by the PUU N insert, which most
robably resulted in a lower stability of the respective
articles. In contrast to reports on core particles substi-
uting the c/e1 region residues by foreign epitopes re-
ulting in a destroyed or diminished HBc antigenicity
Scho¨del et al., 1992; von Brunn et al., 1993), the c/e1
articles described here contain the PUU N insert at aa
osition 78 of core (without any deletion of core resi-
ues) explaining the observed high HBc antigenicity in
he ELISA. This is in line with previous data using the
ame insertion site (Borisova et al., 1996). However, the
educed anti-HBc response toward these particles in
ank voles could reflect structural peculiarities due to
he 45 aa insert (masking of the HBc epitope). This
asking effect was even more pronounced in c/e1 par-
icles harboring the entire putative protective region (aa
PUU N Insertions in Bank Voles
Effect of virus challenge Protection
N antigen
in lungs
G2-specific
antibodies
No. of animals protected/
total no. of animals
5/5 5/5 0/5
3/4 2/4 1/4; (1)a/4
5/5 3/5 (2)/5
4/4 4/4 0/4
5/5 5/5 0/5
1/5 0/5 4/5; (1)/5
2/3 2/3 1/3
1/3 1/3 2/3
l fusion
5/5 5/5 0/5
2/2 2/2 0/2
0/2 0/2ABLE 1
rrying
termina–120) of PUU N (Koletzki et al., 1999). Nevertheless, our
esults confirmed the previously reported data (Koletzki
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370 KOLETZKI ET AL.et al., 1999; Kratz et al., 1999) about the high insertion
apacity of the c/e1 region.
Because of the limited insertion capacity of the C-
erminal region of HBV core, mosaic particles have been
eveloped on the basis of the co-expression of HBV core
nd a HBV core/foreign protein fusion mediated by a
uppressor tRNA-readthrough of a stop codon (Koletzki
t al., 1997). As expected and previously shown for 114-
nd 120-aa long sequences of PUU N (Koletzki et al.,
997, 1999), mosaic particles improved the ability of C-
erminal core/PUU N (aa 1–45) fusions to form core-like
articles dramatically. These core-like particles induced,
s compared to the C-terminal chimeric construct, a
uch stronger PUU N-specific antibody response in
ank voles, probably due to the flexible glycine linker
ocated between core and PUU N in the mosaic con-
truct. However, the mosaic particles did not induce a
rotective immune response, which was in line with our
revious data where mosaic particles carrying aa 1–114
f PUU N induced only a marginal protective response
Ulrich et al., 1999). However, mosaic particles could be
T
PEPSCAN Analysis of the Epitope-Spec
Peptide
used in the
PEPSCAN
PUU virus
challenge
Ant
HBV
core
Non-immunized,
challenged
animals
Fu
co
the N
n n n
1–10 pre 2 2 E
post 2 2 E
6–15 pre 2 2 2
post E 2 E
11–20 pre 2 2 2
post 2 2 2
16–25 pre 2 2 2
post 2 2 2
21–30 pre 2 2 2
post E 2 ˆ
26–35 pre 2 2 2
post 2 2 2
31–40 pre 2 2 2
post 2 2 2
36–45 pre 2 2 2
post 2 2 2
231–240 pre 2 2 2
post ˆ E ˆ
Note. n 5 non-protected; pp 5 partially protected; p 5 protected. The
, 0.2–0.4; K, 0.5–0.8; F, .0.8.
a An animal from the previous study (Ulrich et al., 1998b).dvantageous for the induction of a humoral immune
esponse against “problematic” sequences; we have re-
h
aently observed that the insertion of aa 1–80 of Vranica/
a¨llna¨s N protein abolished the formation of core parti-
les when inserted into c/e1, whereas mosaic particles
ere still formed (Koletzki et al., unpublished data).
The analysis of the PUU N antigenicity and immuno-
enicity of the different core-derived particles by ELISA
evealed more general differences between the expo-
ure of the PUU N sequence on core-like particles dem-
nstrating the c/e1-inserted PUU (Vranica/Ha¨llna¨s) se-
uence as highly antigenic and immunogenic. More pre-
ise information about the structure and surface
xposure of the insert was revealed by PEPSCAN anal-
ses of the epitope-specificity of antibodies in bank voles
mmunized with the various core/PUU particles. Interest-
ngly, only mosaic particles carrying PUU N (strain
ranica/Ha¨llna¨s) were able to induce a strong antibody
esponse directed against aa 36–45. This might be due
o a unique surface presentation of the hantavirus insert
y the mosaic particles (see above). Furthermore, it is
nteresting that only the core-derived constructs, in con-
rast to the synthetic peptide, were able to induce a
f Antibodies in Immunized Bank Voles
ed for immunization of bank voles
ranica/Ha¨llna¨s) aa 1–45 PUU (CG18-20) aa 1–45
us
Fused to
HBV
core at
c/e1
Mosaic
HBV
core
particles
Fused to
HBV
core at
c/e1
Synthetic
peptide
p n pp n na pp p n
ˆ K K K 2 K ˆ 2
ˆ F E E 2 E E 2
E ˆ F ˆ E 2 E 2
2 K F E ˆ 2 E 2
2 2 2 2 2 2 2 2
2 2 2 E 2 2 2 2
2 2 2 2 K 2 2 2
2 2 2 2 K 2 2 2
2 2 E 2 2 2 E 2
2 E 2 E E 2 2 2
2 2 2 2 2 2 2 2
2 2 2 2 2 2 2 2
2 2 2 2 2 2 F K
2 2 2 2 2 2 F F
2 E 2 F 2 2 2 2
2 K 2 F 2 2 2 2
2 2 2 2 2 2 2 2
2 ˆ 2 ˆ ˆ 2 2 E
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371CHIMERIC HBV CORE/PUU N PARTICLESincreased immunogenicity might be due to a special
folding and/or to the multimeric presentation of the han-
tavirus insert by the particulate carrier protein. The dif-
ferences in the epitope-specificity of the antibody re-
sponse observed between the particles carrying the
PUU (Vranica/Ha¨llna¨s) N insert at different positions may
be caused by (a) an altered accessibility/folding of the
hantavirus sequence in the respective core-like parti-
cles, and (b) the different ability of the respective fusion
proteins to form stable particles which could lead to
differences in the antigen uptake and a resulting modi-
fied immune response. Similarly, a HIV-1 Gag sequence
fused to HBV core could be divided into surface-exposed
and not-accessible regions by the use of antibodies
directed against different parts of HIV-1 Gag (Grene et
al., 1997).
Most important, not only the antigenicity and immuno-
enicity of the PUU (Vranica/Ha¨llna¨s) N region but also
he protection of bank voles was dependent on the in-
ertion site within the particulate carrier as only N-ter-
inal and c/e1 constructs induced a protective immune
esponse. These data are in line with previous reports
emonstrating the induction of a protective immune re-
ponse in animal models by chimeric HBV core particles
arrying the foreign insert at the N-terminus or the c/e1
egion of core (Neirynck et al., 1999; for a review see
Ulrich et al., 1998a).
When comparing the protectivity of core-like particles
harboring PUU N sequences of different strains, we had
to recognize in this study that N protein segments of
related PUU strains (Vranica/Ha¨llna¨s vs. CG18–20) were
not as cross-protective as may have been expected:
Whereas c/e1 particles carrying aa 1–45 of CG18–20 N
protein reproducibly protected 80% of the bank voles
completely (see Ulrich et al., 1998b), only 40% of the
animals immunized with the corresponding Vranica/
Ha¨llna¨s N protein-carrying particles were partially pro-
tected against challenge by PUU strain Kazan. This dif-
ference in biological activity is probably due to aa ex-
changes at positions 34/35 within the N protein of both
virus strains (see Figure 1C). The same aa variation was
discussed also as the reason for antigenic variation
between Vranica/Ha¨llna¨s and CG18–20 in recognition by
the monoclonal antibody (Mab) 1C12 (see below), which
is very likely directed against a conformational epitope.
Interestingly, this Mab provides partial protection against
PUU virus (strain Kazan) challenge in the animal model
(Lundkvist et al., in preparation).
The observed differences in the protectivity of Vranica/
a¨llna¨s versus CG18–20 N protein are reflected also by
he epitope-specificity of the antibody responses. Only
he sera of animals immunized with CG18–20-derived
onstructs were found to react with aa 31–40 in the
EPSCAN assay. Peptides used for this assay corre-
pond to the PUU strain Sotkamo which is antigenically
loser to CG18–20 than to Vranica/Ha¨llna¨s in this region nof N (see Fig. 1C). Especially in the region between aa 31
and 40, aa substitutions are present at positions 34/35
(VD in Sotkamo and CG18–20, MY in Vranica/Ha¨llna¨s).
This might be the reason for the non-reactivity of sera
from animals immunized with Vranica/Ha¨llna¨s-derived
proteins with this peptide.
Based on the PUU (strain CG18–20) N protein (aa
1–45), we compared the immunogenicity and protectivity
of the synthetic peptide with the corresponding core
particles carrying the peptide at the c/e1 site. In line with
previous data (Ulrich et al., 1998b) the core particles are
highly immunogenic and protective. Here we confirmed
that peptides are of lower immunogenic (and protective)
potential than the multimeric particulate antigens based
on HBV core-like particles as earlier described for chi-
meric core/rhinovirus peptide particles (Francis et al.,
1990). However, it could not be excluded from our data
that a non-particulate hantavirus N protein derivative (for
example a monomeric HBV core fusion protein) is able to
induce a protective immunity in the animal model, as
glutathion S transferase fusions were also able to protect
bank voles against a hantavirus challenge (Lundkvist et
al., 1996). Therefore, experiments to study the capability
of monomeric HBV core/PUU N fusion proteins to pro-
vide a protective immunity are in progress.
As PUU virus infection did not induce disease in bank
voles, indirect evidence based on N antigen expression
in lungs and induction of G2-specific antibodies could be
used as markers of infection (Lundkvist et al., 1996).
Recently, we observed an increase of the titer of N-
specific antibodies in non-protected bank voles after
hantavirus challenge (Ulrich et al., 1998b). When compar-
ng the epitope-specificity of the antibody response of
on-protected and partially/completely protected bank
oles prior and post challenge, we detected in the
resent study, by PEPSCAN analyses of the respective
erum pools, an antibody response specific for the pep-
ide aa 231–240 in all non-protected animals after chal-
enge. A similar region was also observed as highly
mmunogenic in sera of PUU-infected humans (Vapalahti
t al., 1995), (experimentally) PUU-infected bank voles
Lundkvist et al., 1996), and DNA-vaccinated mice (Ko-
etzki et al., 2000). Although it must be taken into consid-
ration that the epitope-specificity pattern may show
ariances between individual animals, especially since
he epitope-specificity of the immune response in human
UU infections varied dramatically between different in-
ividuals (Lundkvist et al., 1996; Vapalahti et al., 1995), it
ould be of advantage to use antibodies directed against
he epitope aa 231–240 (lacking in the partially or com-
letely protected animals), in addition to the absence of
antigen in lungs and of G2-specific antibodies in the
erum, as a third marker for differentiation of protected/
on-protected animals.Since aa 1–45 and aa 75-119 of CG18–20 N protein did
ot induce protection in all animals (Ulrich et al., 1998b;
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372 KOLETZKI ET AL.this paper), we combined both regions in one core par-
ticle with the hope to achieve full protection. The simul-
taneous insertion, however, of the two regions into dif-
ferent sites of the HBV carrier molecule did not increase
the protectivity as compared to the construct pHBc1–78/
CG45/78–144 carrying a single internal insertion of aa
1–45 (strain CG18–20; see Table 1). This failure to induce
an increased protection may probably be explained by
the C-terminal insertion site of aa 75–119, which did not
appear to be optimal (see above). Interestingly, immuni-
zation of bank voles with particles carrying aa 75–119 of
CG18–20 N confirmed our previous data about a second
minor protective region in the PUU N protein (Ulrich et al.,
1998b).
Comparing the antibody responses (as measured by
ELISA) between protected and non-protected animals in
pre-challenge sera we did not see any significant differ-
ences. In line with these data, our recent investigations
failed to detect virus-neutralizing antibodies in protected
animals prior to challenge (Ulrich et al., 1998b). As shown
here, there is no obvious difference in the antibody re-
sponse against the very N-terminus of PUU N, as it
occurred in protected as well as in non-protected ani-
mals. Although we cannot exclude a role of these or
other (non-detected) antibodies against discontinuous
epitopes in the protective mechanism, a cellular immune
response seems to be essential in hantavirus N protein-
mediated protection as discussed also by other authors
(Asada et al., 1988; Schmaljohn et al., 1990; Xu et al.,
1992; Yoshimatsu et al., 1993). On the other hand, there
are clearly findings supporting also a role for humoral
immunity in protection as shown by passive transfer of
N-specific Mabs (Yoshimatsu et al., 1993, 1996; Lundkvist
et al., in preparation) which could be explained by pre-
entation of PUU N-derived peptides on virus-infected
ells, binding of the N-specific antibodies on these pre-
ented peptides and interaction of the bound antibodies
ith cytotoxic cells (antibody-dependent cell-mediated
ytotoxicity, ADCC).
Taken together, our investigations give further evi-
ence for the c/e1 region to be the insertion site of
hoice from the following points of view: insertion capac-
ty, antigenicity, immunogenicity, and protectivity. The
rotective potential of HBV core particles was demon-
trated to be dependent also on the PUU strain se-
uence inserted into the c/e1 site. Interestingly, the low
rotective potential of aa 1–45 of Vranica/Ha¨llna¨s N
(compared to the corresponding segment of CG18–20)
could be overcome by the use of core particles carrying
the entire putative protective region aa 1–120 of Vranica/
Ha¨llna¨s N (Koletzki et al., in preparation) giving further
evidence for the presence of at least two separate pro-
tective regions at the N-terminus of PUU N protein. As
confirmed by these data, chimeric HBV core particles
represent a promising carrier moiety for hantavirus vac-
cine development.MATERIALS AND METHODS
Plasmids, bacterial strains, and synthetic peptide
For cloning of the PUU N coding sequence, HBV core-
encoding plasmids carrying a unique BamHI restriction
site at different positions were used (Ulrich et al., 1999).
or expression of the HBV core-derived fusion proteins,
he E. coli K12 strains K802 (Sambrook et al., 1989), K802
[pISM3001] (Smiley and Minion, 1993) and M15 [pREP4]
(Qiagen, Hilden, Germany) were used, whereas the
screening for recombinant plasmid DNA was performed
in E. coli K12 XL-1 Blue (Sambrook et al., 1989). A PUU N
oligopeptide (aa 1–45, strain CG18–20) was synthesized
by Neosystem (Strasbourg, France).
Antibodies
Polyclonal PUU (strain Vranica/Ha¨llna¨s) N protein-spe-
cific antibodies were generated by immunization of rab-
bits with the recombinant complete (aa 1–433) N protein
(Sibold et al., unpublished data). A HBc/HBe-specific
hyperimmune serum was generated in rabbits with re-
combinant HBV core particles (Ulrich et al., 1993).
Construction of plasmids
Manipulation of plasmid DNA was performed accord-
ing to standard procedures (Sambrook et al., 1989). Re-
striction enzymes and T4 DNA ligase were purchased
from Boehringer Mannheim (Mannheim, Germany) or
MBI Fermentas (Vilnius, Lithuania). Oligonucleotides
were obtained from BioTez (Berlin, Germany). The se-
quence encoding PUU N aa 1–45 (strain Vranica/Ha¨ll-
na¨s) was obtained by PCR amplification using the plas-
mid pHBc1–144/VR1–433 (Koletzki et al., 1999) as tem-
plate sequence. The primer oligonucleotides 59- AG GAT
CCC ATG AGT GAT CTG ACA GAT ATC CAA (named
VR-N) and 59- AAA GAT CTT GCA GTG TGT TTT TGT TAA
CGT C (named VR-45-C) contain a BamHI site and a BglII
site, respectively. For DNA amplification, the PCR product
was cloned into the pCR 2.1 plasmid (Invitrogen, Leek,
Netherlands) and sequenced by Sanger chain termina-
tion method. A BamHI-BglII fragment was isolated and
subsequently ligated into the different BamHI-linearized
HBV core-encoding plasmids (see Fig. 1A). The nomen-
clature of plasmids indicates the insertion site (aa posi-
tion) in the HBV core protein (Koletzki et al., 1999).
Furthermore, for comparison of distinct PUU strains,
three constructs encoding similar HBV core-derived fu-
sion proteins with 45 aa long segments of PUU (strain
CG18–20) N (Fig. 1B) were used as described previously
(Ulrich et al., 1998b, 1999; for comparison of the aa
sequences, see Fig. 1C).
Expression and purification of recombinant proteinsThe expression of the HBV core-derived proteins and
the purification of the core-like particles were performed
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373CHIMERIC HBV CORE/PUU N PARTICLESas described previously (Koletzki et al., 1999). Briefly,
cleared native lysates of E. coli cells were concentrated
by ammonium sulfate precipitation at 30% saturation.
The precipitates were fractionated using a discontinuous
sucrose gradient (20–50%; 28000 rpm for 20 h at 4°C in
a Beckman L7–55, rotor SW 28 centrifuge). Fractions of
2 ml were analyzed by UV/VIS spectrometry at 280 nm for
protein detection followed by SDS-PAGE and immuno-
blotting. The protein concentration was determined by
Bradford analysis. The sucrose gradient-purified proteins
were concentrated and purified from sucrose by ultrafil-
tration using BIOMAX-50K membranes (Millipore, Bed-
ford, MA), a fivefold volume of PBS in a Megafuge 1.0R
(swing-out rotor, Heraeus, Hanau, Germany) at 2000 rpm
and 4°C. Lyophilisation was carried out in a Edwards
Freeze Dryer Supermoduy at 5x E-2 mbar with a plate
temperature of 220°C for 12 h. Samples were stored at
220°C until further use.
Electron microscopy
Core-like particles were analyzed by negative staining
transmission electron microscopy as previously de-
scribed (Gelderblom et al., 1967). Briefly, sucrose-gradi-
ent purified fractions were adsorbed to 400-mesh copper
grids, negatively contrasted using 1% uranyl acetate and
evaluated in a Zeiss EM 10A.
SDS-PAGE and Western blotting
Protein samples were separated by electrophoresis in
15% SDS polyacrylamide gels (Bio-Rad, Munich, Ger-
many). Immunoblotting was performed according to a
standard protocol as described elsewhere (Koletzki et
al., 1999). Briefly, after semi-dry transfer, cellulose nitrate
filters were blocked with 5% dry milk/PBS/0.1% Tween 20.
The rabbit anti-HBc/HBe serum and the PUU (strain
Vranica/Ha¨llna¨s) N protein-specific rabbit serum were
diluted 1:50 and 1:100, respectively, in PBS/0.1% Tween
20. For the detection of the antigen-antibody reaction the
PAP system (DAKO Diagnostika, Hamburg, Germany)
was used. Peroxidase-mediated staining was performed
by adding 4-chloro-1-naphthol (Sigma, Deisenhofer, Ger-
many) and H2O2.
Sandwich ELISAs
For detection of HBV core and PUU N antigenic deter-
minants two different sandwich ELISAs were used as
previously described (Koletzki et al., 1999). Briefly, plates
were coated with human anti-HBc-IgG (2.5 mg/ml). After
locking, plates were incubated with 100 ml per well of
he recombinant antigen (1 mg/ml) in 1% BSA/PBS for 1 h
t 37°C followed by five washing steps. For detecting the
Bc antigenicity, peroxidase-labeled human anti-HBc-
gG (2.5 mg/ml) was used. The PUU N-specific assay
plates were incubated with the N protein-specific anti-
serum (250 ng/ml) for 1 h at 37°C followed by peroxi-dase-labeled anti-rabbit-IgG (0.1 mg/ml). Detection was
erformed by adding substrate buffer (1 mM 3,39, 5,59-
etramethylbenzidinehydrochloride in 0.2 M citrate buffer,
H 4.0; 3 mM H2O2; Sigma). The reaction was stopped by
the addition of 2 N sulphuric acid and the optical densi-
ties were measured at 450/620 nm.
Antibody ELISAs
The immune response in bank voles (see below)
against HBV core was detected by using an anti-HBc
ELISA (Sorin Biomedica, Saluggia, Italy). Serological re-
sponse against PUU N was measured by using different
inhouse anti-PUU (strain Vranica/Ha¨llna¨s) N-specific as-
says (Sibold et al., 1999; Cifire et al., unpublished data).
The inhouse assays were based on recombinant E. coli-
expressed N protein derivatives (aa 1–213, aa 1–39/213–
433 and aa 40–340) as test antigens. Plates were coated
with recombinant antigen (0.2 mg/ml or 0.4 mg/ml) at 4°C
vernight. After blocking, serum samples (1:200 in 1%
SA/PBS) were applied. After washing, peroxidase-la-
eled anti-mouse antibodies (1:1000 in 5% calf/sheep
erum in PBS; DAKO Diagnostika, Hamburg, Germany)
ere added and detection was performed according to
nstructions of the manufacturer (see above).
nimal immunization and PUU virus challenge
To study immunogenicity of the constructs as well as
rotection after hantavirus challenge, 4–10-week-old
ank voles from a PUU virus-free colony (Lundkvist et al.,
996, 1997) were immunized with the recombinant core-
ike particles or the synthetic peptide, following a stan-
ard protocol (Lundkvist et al., 1995; Ulrich et al., 1998b).
riefly, animals were subcutaneously vaccinated with 50
mg of proteins in PBS emulsified in Freund’s complete
adjuvant. The second and third immunization was given
in intervals of three weeks, using the same amount of
protein but in incomplete Freund’s adjuvant and PBS,
respectively. Sera were taken one day before challenge
for measuring the humoral immune responses. Virus
challenge was performed with 104 ID50 units of PUU virus
(strain Kazan; Lundkvist et al., 1995). Animals were sac-
rificed after an additional 21 days. Lung tissue samples
were analyzed for the presence of N antigen (for details
see Lundkvist et al., 1991, 1995, 1996). Post-challenge
sera were analyzed by anti-PUU N protein-specific
ELISAs (see above) and anti-PUU G2-ELISA as de-
scribed previously (Lundkvist et al., 1996).
PEPSCAN assay
To determine the epitope-specificity of the humoral
immune response, a PEPSCAN assay covering the com-
plete N protein of PUU (strain Sotkamo) in 10mer pep-
tides with a 5 aa shift (Lundkvist et al., 1995) was used.
Sera of immunized bank voles (prior- and post-challenge
separately) were pooled from 3 different animal groups
374 KOLETZKI ET AL.(found to be non-protected, partially protected, or com-
pletely protected against challenge virus). Peptide-
coated pins were blocked for 2 h at room temperature
with buffer A (2% BSA/0.1% Tween 20 in PBS) and sub-
sequently incubated with the sera (diluted 1:200 in buffer
A) overnight at 4°C. After washing with 0.05% Tween
20/PBS the pins were incubated with alkaline phos-
phatase-conjugated AffiniPure F(ab9)2 fragment goat
anti-mouse IgG (H&L; Jackson, West Grove, Pennsylva-
nia; 0.6 mg/ml diluted in buffer A) for 1 h at room tem-
perature. After washing, detection was performed with
p-nitrophenyl phosphate substrate at 405 nm. Sample
values were regarded as positive if the absorption was
.0.081 (mean value 1 standard deviation of the negative
control).
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